Mitogen-activated protein kinase (MAPK) and AKT pathways are frequently co-activated in melanoma through overexpression of receptor tyrosine kinases, mutations in their signaling surrogates, such as RAS and BRAF, or loss of negative regulators such as PTEN. As RAS can be a positive upstream regulator of PI3-K, it has been proposed that the loss of PTEN and the activation of RAS are redundant events in melanoma pathogenesis. Here, in genetically engineered mouse models of cutaneous melanomas, we sought to better understand the genetic interactions between HRAS activation and PTEN inactivation in melanoma genesis and progression in vivo. We showed that HRAS activation cooperates with Pten þ /À and Ink4a/ArfÀ/À to increase melanoma penetrance and promote metastasis. Correspondingly, gain-and loss-of-function studies established that Pten loss increases invasion and migration of melanoma cells and non-transformed melanocytes, and such biological activity correlates with a shift to phosphorylation of AKT2 isoform and E-cadherin down-regulation. Thus, Pten inactivation can drive the genesis and promote the metastatic progression of RAS activated Ink4a/Arf deficient melanomas.
Introduction
RAS activation is a common and potent oncogenic event in human solid tumors, including melanoma. The relevance of RAS-RAF-MAPK pathway in melanoma pathogenesis is evidenced by high frequency BRAF mutations (Davies et al., 2002) and less common yet reciprocal NRAS mutations (Tsao et al., 2004) . Activating mutations of NRAS are found in as many as 56% of congenital nevi, 33% of primary and 26% of metastatic melanoma samples (Chin et al., 2006) . Although NRAS is the most commonly mutated RAS family member, mutations on KRAS (2%) and HRAS (1%) are also observed in human melanomas (Forbes et al., 2008) . In particular, HRAS mutation was reported to be found in 7.7% of the nodular melanoma subtype (Jafari et al., 1995) .
Genetic evidence of a pathogenetic role for the RAS-RAF-MAPK pathway in melanoma is derived from a melanoma-prone condition in mice transgenic for melanocyte-directed HRAS V12G or NRAS Q61K alleles and null for p16 INK4a and/or p19 ARF tumor suppressors (Chin et al., 1997 (Chin et al., , 1999 Sharpless et al., 2003; Ackermann et al., 2005) . Additionally, BRAF, a key effector of RAS signaling, is the most frequently mutated gene in human melanocytic neoplasms with frequencies of 82% of benign nevi and 66% in melanomas (Davies et al., 2002; Pollock et al., 2003) . Melanocyte-directed expression of BRAF V600E can induce nevoid hyperpigmentation phenotype in mice (Dankort et al., 2009; Dhomen et al., 2009; Goel et al., 2009) with rare progression to melanoma (Dhomen et al., 2009; Goel et al., 2009) .
Although activation of the RAS-RAF signaling cascade has been recognized as an obligate event in melanocyte transformation, Khavari and colleagues have demonstrated that activation of BRAF-MAPK requires concomitant AKT activation to affect melanoma development (Chudnovsky et al., 2005) . Consistent with the importance of PI3K-AKT pathway, over 60% of human melanomas exhibit activated AKT (Dhawan et al., 2002) , and mutational inactivation and/or deletion of the PI3K negative regulator, PTEN, occurs in 5-15% of uncultured melanoma specimens and metastasis, 17% of melanoma short-term cultures, and 30-40% of established melanoma cell lines (Guldberg et al., 1997; Birck et al., 2000; Tsao et al., 2004; Lin et al., 2008) . Mouse modeling has also demonstrated that Pten þ /À Ink4a/Arf þ /À mice do succumb to melanoma at low frequency (You et al., 2002) and robust melanoma formation and metastases can occur upon combination with activated BRAF (Dankort et al., 2009) .
The PI3K-AKT signaling pathway can be activated by receptor tyrosine kinases. Active PI3K phosphorylates and converts the lipid phosphatidylinositol (4,5) bisphosphate into phosphatidylinositol (3, 4, 5) triphosphate, which in turn activates AKT through PDK1mediated phosphorylation. PTEN negatively regulates PI3K signaling by dephosphorylating phosphatidylinositol (3, 4, 5) triphosphate, converting it back to phosphatidylinositol (4,5) bisphosphate. Therefore, deletion or inactivation of PTEN results in constitutive AKT activation (Cully et al., 2006; Salmena et al., 2008) . On the other hand, RAS proteins can positively regulate the PI3K-AKT pathway by direct binding of RAS to the p110 catalytic subunit (Gupta et al., 2007) or by activating an autocrine signaling pathway involving EGFR family ligands (Bardeesy et al., 2005) . As PTEN inactivation and RAS-activating mutation can both target the PI3K pathway to drive constitutive AKT activation, it has been proposed that RAS mutation and PTEN inactivation are redundant events in tumorigenesis, as suggested by a reciprocal trend of their mutations in human melanoma and endometrial carcinoma (Ikeda et al., 2000; Tsao et al., 2000) . However, constitutive AKT1 activation in mouse has resulted in a milder cancer phenotype than complete PTEN inactivation (Stambolic et al., 2000; Majumder et al., 2003; Trotman et al., 2003; Wang et al., 2003; Ma et al., 2005) , pointing to AKT independent activities of PTEN in tumorigenesis (Blanco-Aparicio et al., 2007) . Similarly, while the expression of oncogenic KRAS or conditional PTEN deletion in the ovarian epithelium gives rise to preneoplastic ovarian lesions, the combined effect of these two mutations in the ovary leads to invasive and widely metastatic endometrioid ovarian adenocarcinomas with complete penetrance and a disease latency of only 7 weeks (Dinulescu et al., 2005) . In this study, we addressed the potential collaborative interactions between RAS activation and PTEN inactivation on the genetic level.
Results

Pten inactivation cooperates with HRAS V12G in melanoma genesis in vivo
We had previously shown that Tyr-HRAS V12G Ink4a/ Arf À/À compound mutant mice (hereafter 'RAS-Ink4a/ Arf') developed non-metastatic cutaneous melanomas with short latency and high penetrance (Chin et al., 1997 (Chin et al., , 1999 Kim et al., 2006) . The occurrence of PTEN loss in advanced melanoma prompted us to determine whether Pten inactivation can cooperate with HRAS activation to drive melanoma progression. Given that Pten nullizygosity is embryonic lethal (Di Cristofano et al., 1998; Suzuki et al., 1998) , we studied the melanoma phenotype of the RAS-Ink4a/Arf model on Pten þ / þ and Pten þ /À background.
Inactivation of one copy of Pten in RAS-Ink4a/Arf mice led to an earlier onset of melanoma and decreased overall melanoma-free survival ( Figure 1a and Table 1 ; P ¼ 0.0002). Although median survival was not notably different (median survival 21.6 vs 18.9 weeks, Supplementary Figure 1 ), melanoma-free survival was significantly decreased by Pten heterozygosity (29.6 vs 18.9 weeks comparing RAS-Ink/Arf mice with Pten þ /À vs Pten þ / þ genotypes). In the absence of melanocytespecific expression of activated RAS, the Pten þ /À Ink/ ArfÀ/À mice showed a median survival of 19.4 weeks, and did not develop melanomas (Supplementary Figure  1 ). In the period before the appearance of nonmelanoma tumors, 75% of the Pten þ /À RAS-Ink4a/ Arf mice developed melanoma compared with 35.7% of mice with wild-type Pten (Table 1) . Histopathologically, these primary spindle-cell tumors are similar to those observed in the melanomas from the RAS-Ink4a/Arf model (Chin et al., 1997 (Chin et al., , 1999 . Melanocytic lineage of Pten þ /À RAS-Ink4a/Arf cutaneous tumors was confirmed by expression of melanocytic markers on protein and RNA level (Figures 1b and c) . These findings clearly establish that activated RAS and loss of Pten cooperate to derive the genesis of melanoma on the Ink4a/Arf null background.
Extensive experience with the RAS-Ink4a/Arf model has established that metastasis does not occur in this model (Chin et al., 1997 (Chin et al., , 1999 Bardeesy et al., 2001 Bardeesy et al., , 2005 . Among the 21 tumor-bearing RAS-Ink4a/Arf mice heterozygous for Pten, full histological surveys uncovered one case of melanoma metastasis of the lung and one case with metastasis in a draining lymph node, although tissue availability only enabled melanocyte marker confirmation in the former (tyrosinase and Dct/ TRP2 positive; Figure 1b ). Although sample size is small, these observations prompted an examination for a potential role of Pten in suppression of melanoma metastasis.
Loss of PTEN enhances invasion of primary and transformed melanocytes
We next assessed the impact of Pten status on the migration and invasion activity of RAS-Ink4a/Arf melanoma cells in vitro ( Figure 2 ). First, we asked whether Pten protein levels in early-passage melanoma cultures that were derived from a spontaneously arising tumor track with migratory and invasive activity. We selected three tumors with high, intermediate or absent Pten protein levels (AL4, CN41 and CN44, respectively) ( Figure 2a ); early passage CN44 cells show absence of both Pten mRNA and protein with retention of the Pten gene consistent with epigenetic silencing (Figure 2b ). Using the modified Boyden chamber assay, the level of Pten expression negatively correlated with invasion Cooperation of Pten loss and RAS activation C Nogueira et al through the Matrigel (Figure 2c ). Second, we observed an overall lower level of invasive activity across four independent RAS-Ink4a/Arf Pten þ / þ melanoma cell lines when compared with five independent RAS-Ink4a/ Arf Pten þ /À melanoma cell lines ( Figure 2d ). Third, these correlations in tumors aligned well with Pten knockdown and reconstitution experiments in vitro and in vivo. Specifically, RNA interference-mediated knockdown of Pten in a Pten þ / þ RAS-Ink4a/Arf melanocyte and melanoma cell lines using two independent short hairpin RNAs (sh4 and sh11 with documented efficient knockdown of Pten protein levels) showed increased invasion in non-transformed melanocyte culture (C140) ( Figure 3a ) as well as in melanoma cells CN116 (Figure 3b ), both were derived from RAS-Ink4a/ Arf mice with intact Pten. Similar results were obtained with AL4 RAS-Ink4a/Arf Pten þ / þ melanoma cell line ( Supplementary Figure 2 ), demonstrating increased invasion in Boyden chamber in vitro compared with the control that was transduced with empty vector. Although we noted an increase in proliferation by Pten loss (Figure 3c ), the level of invasion was still markedly increased when normalized for proliferation rates (see Materials and methods). In vivo, Pten knockdown resulted in reduced melanoma-free survival upon subcutaneous implantation of these melanoma cells in severe combined immunodeficient mice ( Figure 3d ). Finally, Adenoviral-mediated Pten reconstitution in CN44 melanoma cells decreased invasion relative to green fluorescence protein (GFP)-expressing adenovirus control cells (Figure 3e , P ¼ 0.02). Together, these data show that Pten levels can influence the invasive potential of primary and transformed melanocytes.
PTEN inactivation correlates with downregulation of E-cadherin
Many PTEN biological functions have been linked to its lipid phosphatase activity through, which Cooperation of Pten loss and RAS activation C Nogueira et al phosphatidylinositol (3,4,5) triphosphate is converted to phosphatidylinositol (4,5) bisphosphate resulting in inactivation of AKT. At the same time, it is clear that PTEN exerts functions that are apparently mediated through AKT-independent pathways. Of relevance to the current study, PTEN has been shown to modulate actin-cytoskeletal organization, focal contacts, and directional cell motility by focal adhesion kinase (FAK) and can physically interact with E-cadherin at junctional complexes to stabilize cellcell contacts, thereby suppressing invasiveness (Kotelevets et al., 2005; Vogelmann et al., 2005) . In our model system, we sought to better understand the molecular action of Pten by assessment of known targets of Pten pathway ( Figure 4 ). Early passage of RAS-Ink4a/Arf Pten þ /À melanoma cells showed consistent E-cadherin downregulation relative to RAS-Ink4a/Arf Pten þ / þ controls; in contrast, the levels of p-AKT, p-FAK, and p-ERK did not track consistently with Pten genotype (Figure 4a ). Although increased p-STAT3 was observed in RAS-Ink4a/Arf Pten þ /À cell lines relative to RAS-Ink4a/Arf Pten þ / þ controls, Pten knockdown in CN116 and AL4 RAS-Ink/Arf Pten þ / þ melanoma cells failed to show any enhancement in p-STAT3 as well as p-AKT and p-FAK (Figure 4b; Supplementary Figure 2) ; whereas, Pten knockdown in primary RAS-Ink4a/ ArfÀ/À melanocytes resulted in increased phosphorylation of these molecules (Figure 4c ). In contrast, Pten knockdown results in consistent downregulation of Ecadherin expression in both melanocyte and melanoma cell lines. Conversely, Pten reconstitution was associated with no change in p-STAT3, p-FAK, and p-ERK, a modest decrease in p-AKT, and robust increase in E-Cadherin (Figure 4d ). In both CN116 and AL4 cells, Pten knockdown correlated well with loss of E-cadherin protein and mRNA expression ( Figures 4b, e and Supplementary Figure 2B and C). As loss of E-Cadherin has been linked to epithelial-to-mesenchymal transition and progression, our data raised the possibility that PTEN-mediated modulation of E-cadherin expression may be integral to the impact of PTEN on the invasive phenotype of melanoma. Indeed, RNA interference (RNAi)-mediated knockdown of E-Cadherin resulted in increased invasion of CN116 cells (Figure 4f , P ¼ 0.04).
PTEN inactivation enhances invasion of human melanoma cells
To establish the human relevance of our findings, we next assessed the effect of PTEN loss on invasion as well as on p-AKT in human melanoma cell lines. In line with our murine studies, small interfering RNA (siRNA)mediated knockdown of PTEN in WM1366, human Cooperation of Pten loss and RAS activation C Nogueira et al melanoma cells harboring NRAS Q61I mutation resulted in increased invasion without a significant increase of AKT phosphorylation compared with siNT (non-targeting) control (1.34 fold, P ¼ 0.00008) (Figure 5a ). In addition, we investigated the effect of PTEN reconstitution in human melanoma cells WM793A and 1205Lu harboring BRAF V600E mutation and PTEN loss. Previously, Stahl et al. (2003) have shown that reconstitution of PTEN expression in PTEN null melanoma cell lines leads to significant decrease in AKT phosphorylation and apoptosis. Here, to assess the impact of PTEN on invasion, PTEN level was titrated to avoid activation of cell death associated with high-level expression (Figure 5b ). At this level of ectopic PTEN expression in WM793A and 1205Lu cells, PTEN reduced invasion compared with control without significant decrease of AKT phosphorylation (WM793A:
49%; P ¼ 0.003 and 1205Lu: 24%; P ¼ 0.048) (Figure 5b and data not shown). This is consistent with the study reported by Dankort et al. showing the collaboration between Braf and Pten in melanoma progression (Dankort et al., 2009) . Together these studies support the view that PTEN inactivation enhances invasion of mouse and human melanoma cells harboring RAS-RAF-MAPK pathway activation without significant changes in total AKT phosphorylation.
PTEN inactivation preferentially activates AKT2 among AKT isoforms Intriguingly, treatment with PI3K inhibitor, LY294002, in RAS-Ink4a/Arf melanoma cells led to a decrease in total p-AKT and abrogation of the increased invasion brought about by Pten knockdown (Figure 6a) , suggesting that PI3K-AKT signaling does contribute to the invasion phenotype we observed. Although modulation of PTEN does not track well with total p-AKT levels in RAS-Ink/Arf melanoma cells (Figures 3 and 4) , the fact that all three isoforms of AKT (AKT1, 2, and 3) are phosphorylated in RAS-Ink/Arf melanoma cells (data not shown and Supplementary Figure 3 ) raised the possibility that Pten may regulate invasion through switching among activated AKT isoforms (AKT1, 2, and 3) without substantially affecting the total amount of active AKT.
To explore further the thesis that specific AKT isoform confers differential activity in melanoma cells, we first examined AKT3 activation because AKT3 is reported to be the predominant AKT isoform in human melanoma (Stahl et al., 2004) . Here, we ectopically expressed a constitutively active form of AKT3 (myristoylated AKT3) in CN116 cells. Although it dramatically elevated AKT3 phosphorylation at Ser 473 without affecting p-FAK and p-STAT3, myr-AKT3 expression actually inhibited invasion (Supplementary Figure 4A ). It is of note that this result is consistent with the anti-invasive role of myristoylated AKT1 in breast cancer cells reported by Bissell and colleagues (Liu et al., 2006) . On the other hand, a dominant negative form of AKT2 expression (Yuan et al., 2003) in invasive CN44 melanoma cells led to inhibition of invasion (Supplementary Figure 4B ), supporting a proinvasive role for AKT2. Furthermore, in line with the thesis that PTEN loss results in switching of AKT isoform, siRNAmediated knockdown of PTEN in the human melanoma cell line WM1366 enhanced level of p-AKT2 without significantly impacting on total pan-isoform p-AKT when compared with siNT (non-targeting) control (Figure 6c ). This can be further corroborated by ELISA measurement, where p-AKT2 levels were found to be significantly higher in PTEN knockdown cells compared with non-targeting siRNA controls (Figure 6d , 15 mg; 1.26 fold (P ¼ 0.024) and 40 mg; 1.15 fold (P ¼ 0.023)). Accordingly, in the mouse, loss of Pten in CN 116 and AL4 melanoma cells was associated with increased p-AKT2 without significant change on total p-AKT (Figure 6b and Supplementary Figure 4) . Together, these data point that PTEN inactivation in RASactivated melanomas promotes invasion through preferential activation of AKT2. 
Cooperation of Pten loss and RAS activation C Nogueira et al
Discussion
Utilizing genetically engineered models, we investigated the interactions of three melanoma prone genetic elements, namely RAS activation, Pten loss and Ink/ Arf deficiency. Previously, RAS activation in mouse model has been shown to cooperate with Ink/Arf inactivation to drive non-metastatic melanomas (Chin et al., 1997) and loss of Pten when combined with loss of Ink/Arf function contributes to melanoma tumorigenesis at low frequency (You et al., 2002) . However, there still exists considerable uncertainty surrounding the genetic interactions of these lesions. Here, using genetically engineered mouse models in vivo and mouse and human cell systems in vitro, we demonstrated synergistic interaction of these three components in melanoma genesis and progression, manifested as accelerated melanoma development and enhanced Figure 6 PTEN loss has more impact on pAKT2 among AKT isoforms. (a) LY294002 treatment decreased p-AKT level of CN116 cells with Pten loss (sh11) (top, immunoblots with indicated antibodies), which correlates with invasive capability (bottom, Boyden chamber assay). Invasion was quantitated by measuring absorbance of crystal violet dye. Representative images of invasion chamber are shown. (b) Immunoblot analysis of CN116 RAS Ink/Arf melanoma cells with EV, Sh4, or Sh11. Note the much higher increase of pAKT2 compared with total pAKT by loss of Pten protein expression. (c, d) PTEN expression was knocked down with small interfering RNA targeting PTEN (siPTEN) in WM1366 and its effect on AKT phosphorylation (total and AKT2) was measured by immunoblotting (c). p-AKT2 level was analyzed by ELISA (d).
Cooperation of Pten loss and RAS activation
C Nogueira et al migration and invasion of melanoma cells from Pten þ / À RAS-Ink/Arf mice compared with Pten þ / þ Ras-Ink/Arf mice. In addition, we have further elucidated the key molecular events acting as points of convergence and distinction of their downstream signaling pathways. Firstly, we observed E-Cadherin downregulation associated with PTEN loss. Secondly, we have shown differential regulation of AKT isoforms by PTEN loss in RAS mutated melanomas. In particular, we observed preferential increase of phospho-AKT2, much less appreciated isoform in melanoma tumorigenesis. Previous work has proposed that RAS activation and PTEN extinction are functionally and genetically redundant, based on the relative reciprocity of NRAS and PTEN alterations observed in human melanomas and cell lines . However, in human melanoma, we found that 14% (2/14) of the NRAS mutated tumor samples harbor Pten loss or mutation (data not shown). Conversely, 17% (2/12) of the melanoma samples with PTEN loss or mutation also contain NRAS mutation (Chin L, unpublished data) . Thus, our observations in the genetically engineered mouse models are relevant for the human disease, as further supported by our work in human cell lines.
PTEN is a major tumor suppressor located on chromosome 10q23-24, the frequently deleted region in multiple tumor types (Li et al., 1997; Steck et al., 1997) . In human melanoma, PTEN is deregulated by genetic mechanisms (mutation and allelic loss; Guldberg et al., 1997; Tsao et al., 1998) as well as by epigenetic silencing such as methylation (Mirmohammadsadegh et al., 2006) or altered subcellular localization (Trotman et al., 2007) . PTEN methylation status serves as a prognostic marker for poor survival (Lahtz et al., 2010) . In our study, murine melanomas derived from Pten þ /À RAS-Ink4a/Arf mice commonly exhibit loss of Pten protein expression, consistent with the observation in human.
AKT kinase family consists of three highly homologous isoforms: AKT1/PKB-a, AKT2/PKB-b, and AKT3/PKB-g. Although structurally similar, each isoforms of AKT have non-overlapping functions in cancer (Gonzalez and McGraw, 2009) . Phenotypic analyses of polyoma middle T and ErbB2/Neu-driven mammary adenocarcinoma mouse models suggest that AKT1 may inhibit and AKT2 may enhance the invasion (Maroulakou et al., 2007) . This is consistent to previous reports that AKT2 expression in breast and ovarian cancer cells increased adhesion, invasion and metastasis, associated with b1 integrin upregulation (Arboleda et al., 2003) . Several mechanisms have been proposed to achieve isoform specific signaling such as distinct tissue distribution, differential activation by extracellular stimuli, distinct intrinsic catalytic activity and substrage specificity, and differential subcellular localization of the AKT isoforms (Gonzalez and McGraw, 2009) . Although the role of PTEN loss in AKT activation is well established, the effect of PTEN loss on the activity of each AKT isoform has not been addressed in detail.
Among the three isoforms, AKT3 is considered to be the predominant isoform activated in melanomas by amplification and somatic activating mutations (Stahl et al., 2004; Davies et al., 2008) . Here, in our mouse melanomas with activated RAS signaling, Pten loss is associated with enhanced invasion accompanied by a shift to increase phosphorylation of AKT2 isoform, which has been linked to invasiveness, without significant change in total amount of AKT activation ( Figure 6 ). Interestingly, Tsichils and colleagues recently reported that it is the balance between AKT1 and AKT2 rather than the amount of total AKT activity that differentially regulates micro-RNA expression, whereby AKT2 induces miR-200 microRNA family, which in turn decreases E-Cadherin expression (Iliopoulos et al., 2009) . In this study, we report an increase on pAKT2 and decrease of E-Cadherin protein levels upon Pten inactivation. It will be of interest to assess if mir-200 is induced in our model and if it is responsible for the observed downregulation of E-Cadherin. In this regard, it is of interest to note that, although quantitative real time PCR analysis revealed that E-Cadherin was downregulated at the transcriptional level following downregulation of Pten expression in RAS Ink/Arf melanoma cells, upregulation of its known transcriptional regulators including Slug, Snail, and Twist was not observed (data not shown). Zeb1 showed small nonsignificant upregulation by Pten loss (1.23 fold for sh4, 1.38 fold for sh11 vs empty vector, data not shown).
In conclusion, we provide genetic evidence in vivo that RAS activation and Pten loss cooperate to drive melanoma genesis and progression in the mouse. Our data encourages more systematic and comprehensive characterization for the activity of each AKT isoforms at distinct stages of melanoma tumorigenesis and in clinical trials when addressing the effect of AKT inhibitors.
Materials and methods
Mouse tumor cohorts
Tyrosinase enhancer-promoter-driven H-RAS V12G transgenic mice in FVB (N10) (Chin et al., 1997) were crossed onto the Pten mutant background in mixed FVB/C57Bl/6 strain (Podsypanina et al., 1999) and the Ink4a/Arf À/À background in FVB (N10) (Serrano et al., 1996) to generate the compound mice Tyr-H-RAS V12G Ink4a/Arf À/À Pten þ / þ and Tyr-H-RAS V12G ; INK4a/Arf À/À Pten þ /À . Mice were observed biweekly for development of tumors or appearance of ill health. Premoribund animals or animals with significant tumor burdens were killed, and detailed autopsies were performed. Tumor specimens were fixed in 10% formalin and embedded in paraffin for histological analyses as previously described (Chin et al., 1997) . In cases in which sufficient specimens were available, primary tumors were adapted to culture to establish derivative cell lines and/or flash-frozen for subsequent analysis.
Melanocyte and melanoma cell culture Melanoma cell lines were derived from mouse tumors by digestion with collagenase and hyaluronidase (2 mg/ml each; Sigma-Aldrich, St Louis, MO, USA) for 2 h followed by cultivation with RPMI 1640 media (Gibco BRL, Gaithersburg, MD, USA) containing 10% fetal bovine serum and 1% penicillin/streptomycin. Melanocyte cultures were generated from newborn mouse epidermis as described (Sviderskaya et al., 1997) and maintained in RPMI 1640 containing 5% fetal bovine serum, 1% penicillin/streptomycin, 200 pM cholera toxin, 200 nM 12-Otetradecanoylphorbol-13-acetate.
RNA analysis
For analyses of gene expression, total RNA was isolated from primary cutaneous melanomas or from cultured cells using Trizol (Gibco BRL, Gaithersburg, MD, USA) according to the manufacturer's protocol. Total RNA was treated with RQ1 DNAse (Promega, Madison, WI, USA) and 1 mg total RNA was used for reverse transcription reaction using Superscript II polymerase (Invitrogen, Carlsbad, CA, USA) primed with oligo(dT). Coding regions were amplified by PCR or quantitative real time PCR using SYBR Green (Applied Biosystems, Foster City, CA, USA) on an Mx3000P real-time PCR system (Stratagene, La Jolla, CA, USA). Ribosomal protein R15 was used as an internal expression control. Primer sequences are as follows: Tyr: F-CCAGAAGCCAATGCACC TAT and R-AGCAATAACAGCTCCCACCA; Trp1: F-ATT CTGGCCTCCAGTTACCA and R-GGCTTCATTCTTGGT GCTTC; Dct: F-AACAACCCTTCCACAGATGC and R-TC TCCATTAAGGGCGCATAG; RAS transgene: F-CAGATC AAACGGGTGAAGG and R-CACTTGCAGCTCATGCAG; R15: F-CTTCCGCAAGTTCACCTACC and R-TACTTGA GGGGGATGAATCG; Pten: F-TTGCAATCCTCAGTTTG TGG and R-TGGCTGAGGGAACTCAAAGT; E-Cadherin: F-CTTTAAGCCCAGCACTCAGG and R-CCTGCTTCCT GAGAAAATGC.
Protein analyses
For immunoblots, lysates were resolved on 4-12% Nu-Page minigels (Invitrogen). Western blots were probed with antibodies against AKT, phospho-AKT (Ser473), PTEN, p44/42 and phospho-p44/42 Map Kinase (Thr202/Tyr204), phospho-STAT3 (Ser727) from Cell Signaling Technology (Danvers, MA, USA). Anti-FAK [pY397] antibody was obtained from Invitrogen, E-CAD and N-CAD from BD Transduction Laboratories (San Jose, CA, USA), and p-AKT2 (Ser474) from Abcam (Cambridge, MA, USA). b-Actin (Santa Cruz Biotechnology, Santa Cruz, CA, USA), b-tubulin (Sigma-Aldrich), and GAPDH (Sigma) protein expression served as loading control. All antibodies were used at 1:1000 dilutions. p-AKT2 level was measured with PathScan p-AKT2 (Ser 474) Sandwich ELISA Kit (Cell Signaling Technology) following manufacturer's protocol. Immunohistochemical staining of tyrosinase (Santa Cruz Biotechnology), and DCT (TRP2) (provided by Dr. Glenn Merlino) (National Cancer Institute, Bethesda, MD, USA) was performed on formalin-fixed paraffinembedded tissues with heat induced epitope retrieval (0.01 M citrate buffer, pH6.0).
siRNAs, plasmids, and viral infection
To knock down Pten using RNAi, Pten short hairpin RNA oligos were designed using iRNAi software (http://www. mekentosj.com/irnai). Pten short hairpin RNA oligos were cloned into the pRetroSuper retroviral vector (Brummelkamp et al., 2002) . Viral supernatants were produced using standard protocols. Retroviral vectors were transfected into 293T cells using the pCL-Eco helper plasmid. Retroviral supernatants isolated at 36 and 48 h after transfection were diluted 1:1 in culture medium and used to infect melanoma cell lines in the presence of 4 mg/ml Polybrene. At 24 h postinfection, the cells were selected for 2 days in growth medium containing 2.5 mg/ ml puromycin. Western blot analysis of cell extracts from cells infected with the Pten short hairpin RNA containing retroviral vectors showed that two Pten-short hairpin RNA oligos (Pten sh4: 5 0 -GGCACAAGAGGCCCTAGAT-3 0 and Pten sh11: 5 0 -AGACAAGGCCAACCGATAC-3 0 ) show efficient Pten knockdown. Adenoviruses for PTEN was provided by Dr. Jin Q. Cheng (Moffitt Cancer Center, Tampa, FL, USA). The siRNAs targeting human PTEN was purchased from Cell Signaling Technology and mouse E-Cadherin from Dharmacon (Lafayette, CO, USA).
Boyden chamber
Invasion assay was performed in Matrigel Invasion Chambers (24 well plate format from BD BioCoat, San Jose, CA, USA) or in Chemotaxis Chambers (96 well format from NeuroProbe (Gaithersburg, MD, USA) following coating with Matrigel (BD). Briefly, cells were trypsinized, rinsed twice with phosphatebuffered saline ,resuspended in serum-free RPMI 1640 media, and were loaded on upper chamber and allowed to invade through the Matrigel towards 10% fetal bovine serum for 20 h. Non-invasive cells were removed and remaining cells were fixed and stained with crystal violet stain. Invasive cells were either counted under a microscope (five fields per well) or quantitated through pixel quantification (Richard Rosenman V1.2, Richard Rosenman Advertising & Design), or crystal violet dye was extracted with 10% acetic acid and cells were quantified at OD 560 nm. For loading control and to normalize for differences in cell proliferation, cells were seeded in a regular 24-well plate and allowed to grow for the same time as the incubation in the Boyden chambers after which the cells were stained with crystal violet. Cells were quantified at OD 560 nm after dye extraction and this number was used to normalize the invasion value. Statistical analysis was carried out by t-test.
